In addition, there was a broad spectrum of endocrine and metabolic changes in the PCOS group compared with the control group, including obviously increased triglyceride and low-density lipoprotein (LDL) levels, reduced high-density lipoprotein (HDL) levels, marked increases in the serum concentrations of androgens including testosterone and androstenedione, and an increased ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH). The gene discussed is BRD2; the disease is polycystic ovary syndrome.